Synklino

Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.

Total raised

€30M

€29,800,000

Funding rounds

Investors

distinct backers

Active since

2020-10

latest 2022-06

Funding by year

EUR raised per year

Medium confidence

Raise-next likelihood35

base rate 44% for Series A

Exit likelihood13

base rate 12% (2+ rounds)

Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

2 rounds

Date	Stage	Amount	Investors
2022-06-09	Series A	€30M	—	View deal →
2020-10-07	Other	€0	EIR Ventures,Vaekstfonden	View deal →

same sector or country